Literature DB >> 30187827

Antioxidant Preconditioning Improves the Paracrine Responsiveness of Mouse Bone Marrow Mesenchymal Stem Cells to Diabetic Wound Fluid.

Yashar Mehrbani Azar1, Robyn Green1, Carola Ulrike Niesler2, Mari van de Vyver1.   

Abstract

Mesenchymal stem cells (MSCs) are a promising therapeutic tool for the treatment of nonhealing diabetic wounds. The pathological nature of the niche microenvironment limits the use of autologous cell therapy in diabetic patients. Prolonged exposure of endogenous MSCs to a pathological microenvironment in vivo reduces their ability to respond to environmental cues. This study investigated the effectiveness of ex vivo antioxidant treatment [N-acetylcysteine (7.5 mM NAC) and Ascorbic acid 2-phosphate (0.6 mM AAP)] to restore the paracrine function of diabetic MSCs. Healthy control [bone marrow stem cells derived from wild-type mice (SCWT)] (source: wild-type C57BL/6J mice) (n = 12) and impaired/dysfunctional [bone marrow stem cells derived from ob/ob mice (SCob)] (source: obese diabetic, B6.Cg-Lepob/J mice) (n = 12) MSCs were isolated. Ex vivo treatment groups (SCWT vs. SCob) were as follows: (1) no treatment (baseline phenotype), (2) stimulated with diabetic wound fluid (DWF) (baseline response), (3) antioxidant preconditioning (preconditioned phenotype), and (4) antioxidant preconditioned with subsequent stimulation with DWF (preconditioned response). The paracrine responsiveness on both the molecular (mRNA expression of 80 cytokines and receptors, quantitative polymerase chain reaction microarray) and protein (23-plex bead-array Luminex assay) level was assessed. At baseline, 31 genes were overexpressed (> × 2-fold) and 39 genes were underexpressed (> × 2-fold) in SCob versus SCWT. In conditioned media, significant differences (P < 0.05) were detected at baseline for two proinflammatory cytokines [tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ)], four chemokines [keratinocyte chemoattractant (KC), granulocyte colony-stimulating factor (GCSF), Eotaxin, and macrophage chemoattractant protein (MCP1)], and one anti-inflammatory cytokine [interleukin 10 (IL10)]. Following stimulation with DWF, significant differences (P < 0.05) were detected in the secretion of two chemokines [granulocyte macrophage colony-stimulating factor (GMCSF) and Eotaxin], three proinflammatory cytokines (TNFα, IFNγ, and IL9), and four anti-inflammatory cytokines (IL10, IL4, IL13, and IL3). Antioxidant preconditioning significantly dampened the excessive TNFα response observed in SCob and improved the secretion of IL10. Taken together these data suggest that the combined ex vivo treatment of autologous stem cells with NAC and AAP could potentially be an effective strategy to restore the paracrine function of impaired diabetic MSCs before transplantation.

Entities:  

Keywords:  IL10; TNFα; cytokines; diabetes; mesenchymal stem cells; wound healing

Year:  2018        PMID: 30187827     DOI: 10.1089/scd.2018.0145

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  8 in total

Review 1.  Targeting Stem Cells in Chronic Inflammatory Diseases.

Authors:  Mari van de Vyver; Carine Smith; Yigael S L Powrie
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Safety of Human Adipose Stromal Vascular Fraction Cells Isolated with a Closed System Device in an Immunocompetent Murine Pressure Ulcer Model.

Authors:  Joanna Bukowska; Andrea Alarcon Uquillas; Xiying Wu; Trivia Frazier; Katarzyna Walendzik; Mikaela Vanek; Dina Gaupp; Bruce A Bunnell; Paul Kosnik; Babak Mehrara; Adam J Katz; Barbara Gawronska-Kozak; Jeffrey M Gimble
Journal:  Stem Cells Dev       Date:  2020-02-24       Impact factor: 3.272

3.  Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice.

Authors:  Michaele B Manigrasso; Piul Rabbani; Lander Egaña-Gorroño; Nosirudeen Quadri; Laura Frye; Boyan Zhou; Sergey Reverdatto; Lisa S Ramirez; Stephen Dansereau; Jinhong Pan; Huilin Li; Vivette D D'Agati; Ravichandran Ramasamy; Robert J DeVita; Alexander Shekhtman; Ann Marie Schmidt
Journal:  Sci Transl Med       Date:  2021-11-24       Impact factor: 17.956

4.  Safety and Efficacy of Human Adipose-Derived Stromal/Stem Cell Therapy in an Immunocompetent Murine Pressure Ulcer Model.

Authors:  Joanna Bukowska; Andrea Alarcon Uquillas; Xiying Wu; Trivia Frazier; Katarzyna Walendzik; Mikaela Vanek; Dina Gaupp; Bruce A Bunnell; Paul Kosnik; Babak Mehrara; Adam J Katz; Barbara Gawronska-Kozak; Jeffrey M Gimble
Journal:  Stem Cells Dev       Date:  2020-02-12       Impact factor: 3.272

Review 5.  Adult Stem Cell Therapeutics in Diabetic Retinopathy.

Authors:  Sriprachodaya Gaddam; Ramesh Periasamy; Rajashekhar Gangaraju
Journal:  Int J Mol Sci       Date:  2019-09-30       Impact factor: 5.923

Review 6.  Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells.

Authors:  Christian Sávio-Silva; Stephany Beyerstedt; Poliana E Soinski-Sousa; Expedito B Casaro; Maria Theresa A Balby-Rocha; Antônio Simplício-Filho; Jamille Alves-Silva; Érika B Rangel
Journal:  Stem Cells Int       Date:  2020-11-20       Impact factor: 5.443

Review 7.  Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease.

Authors:  Marcella Liciani Franco; Stephany Beyerstedt; Érika Bevilaqua Rangel
Journal:  Pharmaceutics       Date:  2021-12-21       Impact factor: 6.321

8.  Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients.

Authors:  Karina Karina; Iis Rosliana; Imam Rosadi; Siti Sobariah; Louis Martin Christoffel; Rita Novariani; Siti Rosidah; Novy Fatkhurohman; Yuli Hertati; Nurlaela Puspitaningrum; Wismo Reja Subroto; Irsyah Afini; Difky Ernanda
Journal:  Int J Inflam       Date:  2021-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.